Weighing benefits and risks--the FDA's review of prasugrel.
about
Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.Causes of late mortality with dual antiplatelet therapy after coronary stents.Novel treatments for cardiovascular disease prevention.Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyOutcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review.Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.TRITON and beyond: new insights into the profile of prasugrel.Antiplatelet agents for the treatment and prevention of atherothrombosis.InforMatrix: ADP antagonists in acute coronary syndromes.Modern antiplatelet agents in coronary artery disease.Understanding synergy.Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel.Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention.Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.Platelet-targeted pharmacologic treatments as anti-cancer therapy.Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report.Salt stability--effect of particle size, relative humidity, temperature and composition on salt to free base conversion.Effect of Formulation and Process Parameters on the Disproportionation of Indomethacin Sodium in Buffered Lyophilized Formulations.Salt Stability - The Effect of pHmax on Salt to Free Base Conversion.Stability of pharmaceutical salts in solid oral dosage forms.Benefit-risk assessment: to quantify or not to quantify, that is the question.Standardizing the Benefit-Risk Assessment of New Medicines
P2860
Q35752598-C0888594-4E8A-475D-BDC9-FAA9049D2955Q36484993-0229D72E-F9C5-4812-8D16-031F7834A274Q36573521-A5525F54-F2CA-4E26-8199-5C5DCFAF6AB3Q37548399-94E58686-431E-4792-A283-6932A4DE304FQ37677976-5D5CEBE1-2FAF-4A96-8C15-4D96AD0F249FQ37805903-AA0C4501-60B7-4918-9F39-16041B36F272Q37925007-117F909A-C532-4B3F-ACDC-68A1EC0CFA78Q37925009-FC54DCCD-2DD4-4057-B6FD-5632831B5B1CQ37948506-CD7B1118-3ABC-4C2A-94BF-42CC377EC42AQ37973397-414D0850-56A3-4CA8-82C7-B6962DE1DD89Q38063289-875B6B3C-A855-4BB0-BCD2-788212DA422BQ38065010-D9A248CC-C266-447D-A48B-CFE20279811FQ38127002-0C7D2B3C-922B-4265-B096-F663CB5E2681Q38340126-060E77D7-3412-4A44-8C97-FB46F677917EQ38374175-D7D93EC0-075B-493C-B374-9782DE06F182Q38564142-77786171-4896-499B-84AC-F25BDAEAD4F2Q38657846-9D292A1F-4553-4E03-9203-D67CB6C25A35Q39332214-FC936043-8A65-4F72-9924-6B95B8629AEDQ39766893-36BF62EC-0DFB-403F-BA39-1D2AFB65B1B8Q47441074-BA838481-C888-4894-9458-883FF952D699Q48300521-723383E5-D9B3-4781-9524-8E742EEFE7A2Q50931533-53D006EB-33A8-4275-950B-134C599885E6Q50968375-8B64E485-C50B-4CC8-9D3B-CD29D871A1B2Q52895883-9CF65EC4-E883-4F88-97A3-B6691A9BDBB5Q55934009-4FFE2C26-0CF7-4B50-A187-502474B8FD7C
P2860
Weighing benefits and risks--the FDA's review of prasugrel.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weighing benefits and risks--the FDA's review of prasugrel.
@en
Weighing benefits and risks--the FDA's review of prasugrel.
@nl
type
label
Weighing benefits and risks--the FDA's review of prasugrel.
@en
Weighing benefits and risks--the FDA's review of prasugrel.
@nl
prefLabel
Weighing benefits and risks--the FDA's review of prasugrel.
@en
Weighing benefits and risks--the FDA's review of prasugrel.
@nl
P356
P1476
Weighing benefits and risks--the FDA's review of prasugrel.
@en
P2093
Ellis F Unger
P304
P356
10.1056/NEJMP0907122
P407
P577
2009-09-01T00:00:00Z